Shroom Investor 🍄 – Page 2 – Psychedelics Stocks Investing News & Watch List

Mydecine Innovations Announces Closing of Prospectus Supplement Financing

Mydecine Innovations Group

VANCOUVER, British Columbia, Sept. 19, 2023 -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to... Read More...

1442 views4 min read

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations

Numinus Wellness

The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic operations in certain regions to enhance company performance and improve the overall client experience. Collectively, these activities are expected to save nearly C$1 million of annualized cash expenses,... Read More...

1455 views7 min read

Lobe Sciences, Ltd. Announces The Appointment Of Mathew Lee As CFO

Lobe Sciences

VANCOUVER, British Columbia, September 18, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Of... Read More...

M & A69 views8 min read

Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company

Lobe Sciences

VANCOUVER, British Columbia, September 14, 2023--(BUSINESS WIRE)--Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase a... Read More...

Calendar79 views4 min read

BetterLife Pharma to Host Investors Update Call on September 18, 2023

BetterLife Pharma

BetterLife Pharma Inc.VANCOUVER, British Columbia, Sept. 14, 2023 -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), announces that it will host an invest... Read More...

2831 views4 min read

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

Optimi Health

VANCOUVER, British Columbia, Sept. 14, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased to see the positive and encouraging outcomes from the MAPS Phase 3 MDMA-Assisted Therapy (MDMA-AT) Clinical Trial published today on Nature Medicine. The Compan... Read More...

338 views2 min read

Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Silo Pharma

Investigational New Drug (IND) submission to FDA on target for Q1 2024 SPC-15, is a novel Serotonin 4 receptor agonist against stress, developed in conjunction with Columbia University ENGLEWOOD CLIFFS, NJ, Sept. 12, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on mergi... Read More...

32 views4 min read

Optimi Health Granted Amendment to Dealer’s Licence by Health Canada to Supply Special Access Program

Optimi Health

Optimi Health Corp.VANCOUVER, British Columbia, Sept. 07, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, proudly announced today that Health Canada has approved an amendment to the Company’s Dealer's Licence. The amendment empowers Optimi to embark on the f... Read More...

55 views4 min read

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA

PharmaTher Holdings

TORONTO, Sept. 06, 2023 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has submitted a priority original Abbreviated New Drug Application (“ANDA”) for KETARX™ (racemic ketamine) to the Food and Drug Administration (“FD... Read More...

29 views7 min read

Red Light Holland Submits Permit Application to the Township of Cavan-Monaghan for the Company’s 65,000 Square Foot Mushroom Farm

Red Light Holland

Toronto, Ontario--(Newsfile Corp. - September 5, 2023) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company"), an Ontario-based corporation engaged in the production, growth, and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin t... Read More...

Capital Raise47 views3 min read

Optimi Health Announces Second Tranche of CAD $1,000,000 Secured for Debt Financing

Optimi Health

VANCOUVER, British Columbia, Sept. 05, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi Health” or the “Company”), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce it... Read More...

126 views3 min read

Mydecine Announces Conditional Approval of CSE Listing

Mydecine Innovations Group

VANCOUVER, British Columbia, Aug. 30, 2023 -- Mydecine Innovations Group Inc. (NEO:MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), is pleased to announce that it has made an application and received conditional approval to list its common shares on the Canadian Securities Exchange (the "CSE") subject to fulfilling customary CSE requirements.... Read More...

Financials789 views8 min read

Red Light Holland Reports First Quarter 2024 Results

Red Light Holland

Cash balance of $17.5 million as at June 30, 2023Revenue of $1.2 million (vs 2022: $0.8 million, an increase of 53.1%)Gross profit of $0.5 million (vs 2022: $0.3 million, an increase of 80.9%)Property and equipment value of $4.8 millionTotal assets of $29.2 millionToronto, Ontario--(Newsfile Corp. - August 29, 2023) - Red Light Holland Co... Read More...

M & A142 views18 min read

Cybin to Acquire Small Pharma Inc.

Cybin

- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT pr... Read More...

82 views9 min read

Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million

Cybin

TORONTO, August 24, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today that it has renewed its previously established at-... Read More...

113 views7 min read

Red Light Holland Psilocybin Microdosing Capsules Aimed To Be Distributed by Nubu Pharmaceuticals In Australia Pass 8 Weeks of Stability Testing By CCREST Laboratories

Red Light Holland

Red Light Holland's natural psilocybin microdosing capsules developed from psilocybin truffles grown in the Company's farm in The Netherlands, have received the results of the first completed stability tests for the capsules, confirming stability of psilocybinConfirmation of stability of psilocybin follows the previously announced complet... Read More...

145 views4 min read

Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development

Revive Therapeutics

TORONTO, Aug. 22, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that it has initiated the development of a next generation formulation of... Read More...

Capital Raise667 views4 min read

Psyence Group Announces Closing of Private Placement & Conclusion of Loan Agreement

Psyence Group

TORONTO, Aug. 21, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB:PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it has issued 1,056,441 common shares at a price of CAD$0.12 per common share for gross proceeds of CAD$126,773.... Read More...

1394 views6 min read

Cybin Prepares for GMP Manufacturing of CYB003 Capsules for Phase 3 Trial

Cybin

- CYB003 capsule formulation is designed to be stable, dose flexible, patient-friendly and commercially scalable -- Shipments of CYB003 capsules to clinical sites expected in Q1 2024 -- Recently granted U.S. patent covers composition of matter claims and treatment methods in support of the Company’s CYB003 program until 2041 -TORONTO, Aug... Read More...

Financials1271 views11 min read

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023

Mydecine Innovations Group

VANCOUVER, British Columbia, Aug. 14, 2023 -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces the financial results for the six ... Read More...

Financials872 views9 min read

Cybin Reports First Quarter Financial Results and Recent Business Highlights

Cybin

- Topline clinical data readouts expected in Q3/Q4 2023, including Phase 2 efficacy data for CYB003 and Phase 1 data for CYB004 -- U.S. Food and Drug Administration ("FDA") submission of CYB003 Phase 1/2a data for end of Phase 2 meeting expected in Q4 2023 -- Preparations underway for pivotal studies, including the development of a scalab... Read More...

738 views3 min read

Silo Pharma Engages Clarivate for Intellectual Property and Patent Management

Silo Pharma

Clarivate will monitor, manage, and maintain Company’s expanding IP portfolio ENGLEWOOD CLIFFS, NJ, Aug. 10, 2023 -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, announced today that it has retained the services of... Read More...

25 views4 min read

Optimi Health Announces CAD $3,000,000 Senior Debt Financing

Optimi Health

VANCOUVER, British Columbia, Aug. 10, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian drug research and formulation company licensed by Health Canada to manufacture psychedelic substances such as MDMA and high-quality, GMP-grade natural psilocybin, is pleased to announce the non-dilutive Debt Financing Agreem... Read More...

Calendar141 views3 min read

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023

Numinus Wellness

VANCOUVER, BC, Aug. 9, 2023 - Numinus Wellness Inc. ("Numinus") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Nikhil Handa, CFO, will participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023, at... Read More...

61 views8 min read

Red Light Holland Announces Happy Caps Mushroom Farm Signs Distribution Deal with Longo Brothers Fruit Markets Inc. – Longo’s

Red Light Holland

Happy Caps Mushroom Home Grow Kits will soon be available in over 135 retail stores across Canada, including Longo's 31 locations in southern Ontario.Distribution agreement to commence September 15, 2023.Happy Caps' Lion's Mane, Shiitake, and Oyster mushroom kits sell for $25-$30 (MSRP) via www.HappyCaps.ca, Amazon (both USA and Canada), ... Read More...

277 views8 min read

Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- qEEG study was conducted in healthy individuals in Cohort 4 of the Multiple Ascending Dose arm of the study-- Pro... Read More...

113 views6 min read

Cybin Announces Closing of Overnight Marketed Public Offering of Units

Cybin

TORONTO, August 04, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has closed its previously announced... Read More...

1071 views7 min read

Cybin Initiates Dosing of Final Cohort of its Phase 2 Trial of CYB003 in Major Depressive Disorder

Cybin

- To date, CYB003 has demonstrated a robust psychedelic response and a favorable safety and tolerability profile at doses of up to 12mg -- Phase 2 topline efficacy data expected in Q3/Q4 2023 -TORONTO, August 02, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutica... Read More...

1000 views8 min read

Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement

Psyence Group

VANCOUVER, British Columbia, Aug. 02, 2023 -- Psyence Group Inc. (CSE:PSYG | OTCQB: PSYGF), a clinical-stage life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being (“Psyence”), and Newcourt Acquisition Corp (“Newcourt”) (Nasdaq: NCAC), a special purpose acquisition company (“SPAC”) toda... Read More...

1279 views7 min read

Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Units

Cybin

TORONTO, August 01, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, announced today the pricing of its previously announced overnight ... Read More...

381 views8 min read

Red Light Holland’s Psilocybin Microdosing Homogenized Capsules Receive Finalized Certificate of Analysis by CCREST Laboratories

Red Light Holland

The natural psilocybin microdosing capsules, developed from psilocybin truffles grown in Red Light Holland's farm in The Netherlands, have received the results of the successful final tests required for a Certificate of Analysis.Finalized Certificate of Analysis indicates Red Light Holland's lab tested Truffles meets initial requirement f... Read More...

970 views8 min read

Cybin Announces Overnight Marketed Public Offering of Units

Cybin

TORONTO, July 31, 2023--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that it has launched an overnight marketed pu... Read More...

Financials1102 views6 min read

Red Light Holland Reports 2023 Audited Year End Results

Red Light Holland

Cash balance of $18.5 million as at March 31, 2023Revenue of $3.95 million (vs 2022: $2.3 million, an increase of 69.8%)Gross profit of $1.7 million (vs 2022: $0.6 million, an increase of 176.3%)Property and equipment value of $4.8 millionTotal assets of $30.1 millionToronto, Ontario--(Newsfile Corp. - July 31, 2023) - Red Light Holland C... Read More...

730 views2 min read

Optimi Health Announces Receipt of Purported Termination Notice

Optimi Health

VANCOUVER, British Columbia, July 27, 2023 -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”) has received a termination notice and demand for payment pursuant to a definitive supply agreement (the “Supply Agreement”) with a private entity focused on developing mushroom-based therapeutics. For further... Read More...

Joint Venture882 views7 min read

Cybin Partners With Worldwide Clinical Trials to Support Future Clinical Development of CYB003 in Major Depressive Disorder

Cybin

-Collaboration with Worldwide Clinical Trials provides Cybin with access to a contract research organization with substantial experience supporting multinational psychedelic clinical trials -- Cybin expects to report Phase 2 topline efficacy data for CYB003 in major depressive disorder in Q3/Q4 2023 -TORONTO, July 26, 2023--(BUSINESS WIRE... Read More...

1111 views6 min read

Cybin Announces Phase 2 Cohort 5 Dosing Completion of CYB003 in Major Depressive Disorder

Cybin

- Cohort 5 completed with no safety or tolerability issues, Final cohort 6 is recruiting with dosing expected to commence shortly - - Phase 2 efficacy data for CYB003 in major depressive disorder expected in Q3/Q4 2023 - - U.S. Food and Drug Administration ("FDA") submission of CYB003 Phase 1/2a data for pivotal studies expected following... Read More...

1006 views6 min read

Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101

Bright Minds Biosciences

Bright Minds Biosciences-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders-- BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending do... Read More...

140 views8 min read

Cybin Announces Publication of Sponsored Feasibility Study Validating Kernel’s Flow1 Neuroimaging Technology Measuring Psychedelic Effects on the Brain

Cybin

TORONTO, July 20, 2023--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, commends Kernel, a leader in non-invasive neuroimaging, on their pub... Read More...

711 views5 min read

PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

PharmaTher Holdings

TORONTO, July 18, 2023 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce that it has successfully completed a research study evaluating PharmaPatch™, a proprietary microneedle patch, in delivering N,N-dimethyltryptamine (“DM... Read More...

Financials858 views16 min read

Numinus Wellness Inc. Reports Q3 2023 Results

Numinus Wellness

Q3 2023 revenues grew 713.3% year-over-year to $6.0 million Q3 2023 revenues grew 12.6% from previous quarter Gross profit of $2.1 million, increased 1051.6% year-over-year Staff reductions and operational realignment resulted in $0.6 million of one-time expenses during the quarter Cash position of $13.0 million as at May 31, 2023 Activi... Read More...

LATEST PSYCHEDELICS STOCKS NEWS

Make smarter investment strategies with in-depth news reports

Make smarter investment strategies
with in-depth news reports